Increased production of interleukin-6 by adherent and non-adherent mononuclear cells during 'natural fatigue' but not following 'experimental fatigue' in patients with chronic fatigue syndrome

International Journal of Molecular Medicine

Volumn 3, Issue 2, 1999, Pages 209-213

  Gupta, Sudhir ^a,b   Aggarwal, Sudeepta ^a,b   Starr, Arnold ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic fatigue syndrome; Cytokines; Lymphocytes; Monocytes

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; CELL ADHESION; CHRONIC FATIGUE SYNDROME; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; PHYSIOLOGY; REST;

ADULT; CELL ADHESION; FATIGUE; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; PHYTOHEMAGGLUTININS; REST;

EID: 0033068632     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.3.2.209     Document Type: Article

References (27)

1. Gupta S and Vayuvegula B: A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immunol 33: 319-327, 1991.
2. Straus SE, Fritz S, Dale JK, Gould B and Strober W: Lymphocyte phenotype and function in chronic fatigue syndrome. J Clin Immunol 13:30-40, 1993.
3. Rasmussen AK, Noelsen H, Andersen V, Barrington T, Bendtzen K, Hansen MB, Nielsen L, Pedersen BK and Wilk A: Chronic fatigue syndrome - a controlled cross sectional study. J Rheumatol 21: 1527-1631, 1991.
4. Lloyd A, Wakefield D, Boughton CR and Dwyer JM: Immunological abnormalities in chronic fatigue syndrome. Med J Aust 151: 122-124, 1989.
5. Landay AL, Jessop C, Lennette ET and Levy JA: Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 338: 707-712, 1991.
6. Gupta S: Recent developments in immunological aspects of chronic fatigue syndrome. In: The Clinical and Scientific Basis of Myalgie Encephalomyelitis Chronic Fatigue Syndrome. The Nightingale Research Foundation. New York, pp545-550, 1992.
7. Caligiuri M, Murray C, Buchwald D, Levine PH, Cheney P, Peterson D, Komaroff AL and Ritz J: Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 139: 3306-3313, 1987.
8. Morrison LJA, Behan WH and Behan PO: Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin Exp Immunol 83: 441-446, 1991.
9. Chao CC, Janoff EN, Hu S, Thomas K, Gallagher M, Tsang M and Peterson PK: Altered cytokine release in peripheral blood mononuclear cell cultures from patients with chronic fatigue syndrome. Cytokine 3: 292-298, 1991.
10. Chao CC, Gallagher M, Phair J and Peterson PK: Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 162: 1412-1413, 1990.
11. Linde A, Andersson B, Swenson SB, Ahrne H, Carlsson M, Forsber P, et al: Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 165: 994-1000, 1992.
12. Straus SE, Dale JK, Peter JB and Dinarello CA: Circulating lymphokine levels in the chronic fatigue syndrome. J Infect Dis 160: 1085-1086, 1989.
13. Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff SM and Komaroff AL: Interleukin-1β, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 17: 253-261, 1997.
14. Lloyd A, Gandevia S, Brockman A, Hales J and Wakefield D: Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to exercise. Clin Infect Dis 18 (Suppl.): S142-S146, 1994.
15. Patarca R, Klimas NG, Lugtendorf S, Antoni M and Fletcher MA: Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interactions with cellular sources and pattern of soluble immune mediator expression. Clin Infect Dis 18 (Suppl. 1): S147-S153, 1994.
16. Lever AML, Lesvis DM, Bannister BA, Fry M and Nerry N: Interferon production in post-viral fatigue syndrome. Lancet 1: 101, 1988.
17. Bennett AL, Chao CC, Hu S, Buchwald D, Fagioli LR, Schur PH, Peterson PK and Komaroff AL: Elevation of bioactive transforming growth factor-β in serum from patients with chronic fatigue syndrome. J Clin Immunol 17: 160-166, 1997.
18. Ur E, White PD and Grossman A: Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychol Clin Neurosci 241: 317-322, 1992.
19. Hickie I and Lloyd A: Are cytokines associated with neuropsychiatrie syndromes in humans? Int J Immunopharmacol 17: 677-683, 1995.
20. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, Chrousos GP and Gold PW: Evidence of impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 73: 1224-1234, 1991.
21. Moutschen M, Triffaux JM, Demonty J, Legros JJ and Lefebre PJ: Pathogenic tracks in fatigue syndrome. Acta Clin Belg 49: 247-289, 1994.
22. Papanicolaou DA, Wilder RL, Manologas SC and Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Int Med 128: 127-137, 1998.
23. Gupta S, Aggarwal S, See D and Starr A: Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 31: 149-156, 1997.
24. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JF, DuBoise RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Brown N, Schooley RT and Brus I: Chronic fatigue syndrome: a working case definition. Ann Int Med 108: 387-389, 1988.
25. Whiteside T: Cytokine measurements and interpretation of cytokine assays in human diseases. J Clin Immunol 14: 327-339, 1994.
26. Romagnani S: Biology of TH1 and TH2 cells. J Clin Immunol 15: 121-129, 1995.
27. + T cells secreting Thl and Th2 cytokines. Immunity 2: 271-279, 1995.